Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab with Chemoradiation and Durvalumab for Unresected Locally-Advanced NSCLC
NCT04905316Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2021
- Primary completion
- Jul 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of canakinumab in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 2 years. Started May 2021; status: completed.
02
Drugs
canakinumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04905316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905316.